Guangzhou Qianxun Biotechnology Co., Ltd.
📞 190-2544-6380 (WeChat)
中
Guangzhou Qianxun Biotechnology Co., Ltd.
Focus on animal disease diagnostics, serve the animal health industry
Guangzhou Qianxun Biotechnology Co., Ltd. is located in Guangzhou Science City, engaged in the R&D and production of raw materials and diagnostic reagents for a wide range of animal diseases, as well as technical services and development in the field of biotechnology.
Focused on the animal health industry, we are a professional and comprehensive supplier of diagnostic reagents, raw materials and testing services for livestock, laboratory and companion animal diseases in China.
Over the past five years, our team has led more than 20 research projects including the National Key Technology R&D Program. We have filed 49 invention patents (including 4 PCT patents), been granted 24 invention patents, published 20 SCI papers, and formulated 17 group standards.
Adhering to the founding philosophy of "Quality First, Service First", we leverage our professional R&D and production team to build cost-effective products and provide efficient, excellent services to meet the growing market demand and offer users more products and technical support.
National Advanced Worker, Principal Investigator of the National Key R&D Program, Outstanding Young Scientist of the Chinese Association for Laboratory Animal Sciences
Cong Feng, Ph.D., Researcher, is the founder of Guangzhou Qianxun Biotechnology Co., Ltd. He is currently a researcher at the College of Animal Science and Technology, Zhongkai University of Agriculture and Engineering, teaching Laboratory Animal Science, Avian Diseases, and Special Topics in Veterinary Infectious Diseases. He previously served as a researcher at the Guangdong Academy of Biotechnology (Guangdong Provincial Laboratory Animal Monitoring Center), Director of the New Detection Technology Center, Chairman of OHSC, and Director of the Biosafety Laboratory.
He has long been engaged in the development of novel pathogen detection technologies and pathogenic mechanism research. His main research directions include: development of raw materials and kits for animal disease detection, development of vaccines against major animal infectious diseases, and comprehensive prevention and control technologies for animal diseases. He has led or participated in more than 20 national, provincial and municipal research projects, published 60+ SCI papers as first or corresponding author, and been granted 8 invention patents.
During the COVID-19 pandemic, Dr. Cong Feng's team was among the first to successfully construct the E. coli expression strain for the SARS-CoV-2 N protein. Forgoing potential commercial value, they freely shared it with more than 1,200 research teams worldwide, saving precious R&D time for the pandemic research fight. People's Daily praised this act twice, noting it embodied the research ethos of "caring nothing for personal gain, dedicating to the motherland" and was a microcosm of "writing papers on the land of the motherland".
From a research team to industrial services, Qianxun Bio keeps deepening its roots in animal disease diagnostics
Guangzhou Qianxun Biotechnology Co., Ltd. was established in Guangzhou Science City, officially entering the market of animal disease diagnostic reagents and technical services.
Successfully isolated strains of feline herpesvirus, feline calicivirus, etc., and launched polyclonal antibody varieties for COVID-19, classical swine fever, foot-and-mouth disease, serving research and industrial customers.
Simultaneously launched 30 monoclonal antibodies against animal viruses, covering Getah virus, African swine fever, Seneca virus, avian influenza H9, etc.; expanded companion animal CT/MRI imaging services in Guangzhou.
Continuously launched new products such as CSFV-E2 protein mAb, integrated excellent pet doctor resources in Guangzhou, and provided one-stop support for companion animal health.
Profound R&D accumulation and a professional technical service team
49 invention patents filed, 4 PCT patents, 24 invention patents granted, 20 SCI papers published.
A complete technical platform covering mAb/pAb development, protein expression & purification, virus isolation & culture, and histopathological slide reading.
Serving livestock, laboratory and companion animals across multiple fields, with rich products and application scenarios.
Welcome various forms of industry-academia-research cooperation including vaccine development, paper collaboration, and technology transfer.